Combination of agents that increase the expression of death receptor 5 (DR5) and its ligand, TNF-related apoptosis-inducing ligand (TRAIL), is a novel anti-CRC therapy, and correlate with tumor regression (52). This evidence concerns the gene TNFRSF10B and colorectal carcinoma.